Print

Chimerix, Inc.'s Antiviral CMX001 Abstract Selected for an Oral Presentation at the European Group for Blood and Marrow Transplantation's Annual Meeting  
3/28/2013 8:59:46 AM

RESEARCH TRIANGLE PARK, N.C., March 28, 2013 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced presentations related to the use of its broad spectrum antiviral compound CMX001 at the European Group for Blood and Marrow Transplantation's(EBMT) Annual Meeting being held April 7-10, 2013 in London, United Kingdom. EBMT is a non-profit organization working to improve the outcomes of stem cell transplantation and to inform concerned parties about developments in the field.

The presentations include an oral presentation on antiviral activity of CMX001 in patients with life-threatening adenovirus infection enrolled in an expanded access study, and data on potential predictors of patients likely to have multiple double-stranded DNA viral infections, also from the CMX001 Compassionate Use Program. The oral presentation will take place on Wednesday, April 10 and the poster presentation is on Tuesday, April 9.

Please note that full abstracts are available on the EBMT website at: http://registration.akm.ch/einsicht.php?XNKONGRESS_ID=179&XNSPRACHE_ID=2.

About Chimerix and CMX001
Chimerix is committed to the discovery, development and commercialization of novel, oral antiviral therapeutics designed to transform patient care in areas of high unmet medical need. The Company's proprietary lipid technology has given rise to two clinical-stage lipid acyclic nucleoside phosphonates, CMX001 and CMX157, which have demonstrated the potential for enhanced activity and safety in convenient, orally administered dosing regimens.

Chimerix's lead product candidate, CMX001, is a broad spectrum, oral nucleotide analog lipid-conjugate that blocks replication of double-stranded DNA (dsDNA) viruses, including cytomegalovirus (CMV), adenovirus (AdV), BK virus and herpes simplex virus. CMX001 has completed Phase 2 clinical development for the prevention of CMV in hematopoietic stem cell transplant (HSCT) recipients. Chimerix is also conducting a Phase 2 study in HSCT recipients which is evaluating CMX001 as a preemptive therapy for AdV disease, an often-fatal infection which has no approved therapies. Since 2009, Chimerix has made CMX001 available under expanded access regulations to over 80 transplant centers worldwide for the treatment of over 430 patients with life-threatening dsDNA viral infections. Chimerix anticipates initiating SUPPRESS, its Phase 3 study of CMX001 for the prevention of CMV infection in adults undergoing HSCT, in 2013.

Chimerix is also developing CMX001 as a potential medical countermeasure against smallpox under a contract from the Biomedical Advanced Research and Development Authority (BARDA).

Chimerix's second product candidate, CMX157, an oral nucleotide analog lipid-conjugate in Phase 1 development for the treatment of HIV infection, was licensed to Merck in July 2012.

SOURCE Chimerix, Inc.


//-->